ViGenCell Inc. (KOSDAQ:308080)

Revenue by Product

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2019
Immuno Therapy Drugs Goods	258.45M	Log In
Immuno Therapy Drugs Services	20.50M	Log In
Immuno Therapy Drugs	-	Log In

Revenue by Geography

Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023
Period Ending	Dec 31, 2024	Dec 31, 2019
South Korea	278.95M	Log In
South Korea Growth	1755.73%	Log In